

Index

- Advisory Committee on Genetic Testing (ACGT), UK 189, 353–4
- amsacrine 260
- Amsterdam criteria 74, 75
- androgen receptor (AR) gene, breast cancer risk and 16
- anxiety 343–4
referral eligibility and 344
see also psychological distress
- ascertainment bias 98
- Ashkenazi Jewish population 12–13, 49–51
breast cancer
ipsi- and contralateral breast cancer recurrences 84
survival 94, 95–8, 99
ovarian cancer 43, 58
- Association of British Insurers (ABI) 354–5, 358
- Bannayan–Riley–Ruvalcaba syndrome (BRR) 22
clinical cancer genetic management 33
diagnosis 27
differential diagnosis 30
genetics 28–9
- Bannayan–Zonana syndrome *see* Bannayan–Riley–Ruvalcaba syndrome
- basal cell naevus (Gorlin) syndrome 31, 32
- benchmarks, for cancer genetics services 150–2
- borderline ovarian neoplasms 119
- BRCA1* 8–10, 49, 81–2, 108
BRCA1 syndrome 213–14
founder effects 12–13, 49–51
heterogeneity analysis 13–14
mutations 8–9, 49–53, 237–8
carrier probability 134–7
correction of 377
management of carriers *see* management of high-risk individuals
testing for *see BRCA1/2* testing
- penetrance and prevalence 9–10
- protein function 13
- screening 14, 131–7
see also breast cancer; ovarian cancer
- BRCA1/2* testing 299, 306–35
anticipated rates 308
research into potential uptake 308–35
attendance for education and counselling 313–14, 332
calculating uptake 312
cancer and risk status 333
changes over time 313
eligibility 314
family studies 334
gender differences 334
general population 309
hereditary breast/ovarian cancer families 309–12
literature review 319–31
non-participants 334–5
participation in ongoing research 332
pedigree studies 315
prospective vs retrospective studies 334
research contexts 315–16
study population 312–13
‘time since genetic diagnosis’ as a selection criterion 332–3
type of test 312
uptake amongst attendees 332
- BRCA2* 10–12, 49, 81–2, 108–9
BRCA2 syndrome 213–14
founder effects 12–13, 49–51
heterogeneity analysis 13–14

394 Index

- BRCA2* (*cont.*)
- mutations 11–12, 49–53, 237–8
 - carrier probability 134–7
 - management of carriers *see* management of high-risk individuals
 - testing for *see* *BRCA1/2* testing
 - penetrance and prevalence 12
 - protein function 13
 - screening 14, 131–7
 - see also* breast cancer; ovarian cancer
- BRCAPRO computer program 56–7
- BRCAx* syndrome 14, 214, 346
- breast cancer 204–5
- associated genetic syndromes 7
 - Cowden syndrome 25, 32, 34, 78
 - hereditary non-polyposis colorectal cancer 75–6
 - Peutz–Jeghers syndrome 77–8
 - surveillance recommendations 79
- BRCA1*-associated breast cancer 8–10, 82, 209, 213
- cell cycle proteins and 114–15
 - ipsi- and contralateral breast cancer
 - recurrences 83–92
 - lifetime risk 237–8
 - steroid hormone receptors and 112–14
 - survival 92–100
 - tumour pathology 109–11
 - see also* *BRCA1*
- BRCA2*-associated breast cancer 10–12, 82, 213
- cell cycle proteins and 114–15
 - ipsi- and contralateral breast cancer
 - recurrences 83–92
 - lifetime risk 238
 - male breast cancer 131, 213, 238
 - steroid hormone receptors and 112–14
 - survival 92–100
 - tumour pathology 111–12
 - see also* *BRCA2*
- BRCAx* syndrome 14, 214, 346
- carcinoma in situ (CIS) 205, 206–8
- counselling 172
- early diagnosis 205–6, 253–8
- epidemiology 6
- family history clinics 286–7
- hereditary breast cancer studies 7–8
- low penetrance/modifier genes 15–17
- ovarian cancer relationships 7, 48, 49–53
- prevention 212, 214–15
- chemoprevention 91–2, 212, 215, 241–8
- ethical issues 341–2
- first primary breast cancer 238–50
- lifestyle modification 238–41
- mastectomy 212, 215, 217, 248–50, 286–92
- oophorectomy 91, 212, 214–15, 216–17, 249–50
- second primary breast cancer 250
- referrals 159
- risk assessment 126, 168–70
- pedigree analysis 126–31, 169
 - prediction models 56–7, 126–7, 169–70
- risk factors 160
- family history 6–7
 - HRT 240–1
 - oral contraceptive pill 251, 280
- risk stratification 172
- screening 91, 157–8, 178–9, 253–8
- clinical examination 255
 - examination methods 210
 - interval between examinations 210
 - magnetic resonance imaging 257–8
 - mammography 157–8, 209, 255–7
 - misinformation about 339–40
 - population vs high-risk group screening 208–10
 - self-examination 255
 - ultrasonography 257
- surveillance 91, 216, 217
- survival 82–3, 207–8
- linkage-based studies 92–4
 - mutation-based studies 94–100
 - prospective studies 207–8
 - retrospective studies 208
- treatment 210–12, 259–60
- breast conservation surgery 211, 259
 - chemotherapy 211, 241, 260
 - mastectomy 211, 259
 - radiotherapy 90–1, 211, 259–60
 - strategies 211–12
 - see also* gene therapy
 - see also* management of high-risk individuals
- breast density, tamoxifen effect 245
- British Society for Human Genetics (BSHG) 199
- bystander effect 378

395 **Index**

- c-erb-b2* 113
 CA125 screening 222–3, 224, 225, 277
 cancer centres 145, 198–9
 cancer genetics services 166–92, 194–7, 198–9
 Bannayan–Riley–Ruvalcaba syndrome management 33
 costs and benefits 179–84, 345–6
 Cowden syndrome management 32–3
 education and training 189
 eligibility criteria 344–5
 ethical issues 187–9
 evaluation of 145, 190–2
 genetic counselling 170
 genetic testing 184–7
 identification of individuals with increased risk 167–8
 implementation 190
 management of patients with increased risk 173–7, 178–9, 237–61
 organization 3–4
 recommendations 144–5
 registries 197
 standards 195
 survey of European countries 198–9
 see also referrals; risk assessment; screening; Welsh Cancer Genetics Service
 Cancer Genetics Group (CGG), UK 199
 cancer units 144–5
 carboplatin 278
 carrier probability 134–7
 cell cycle proteins, breast cancer 114–15
 cerebellar dysplastic gangliocytoma 25
 chemoprevention
 breast cancer 91–2, 212, 215, 241–8
 raloxifene 246–8
 tamoxifen 91–2, 242–6, 247–8
 ovarian cancer 213–14, 250–1
 prostate cancer 253
 chemotherapy
 breast cancer 211, 260
 tamoxifen 241
 chemoprotectant genes 376
 molecular chemotherapy 375, 378–9
 ovarian cancer 261, 278–9
 Chk2 mutations 15
 cigarette smoking, breast cancer risk and 17, 239–40
 cisplatin 260, 278, 377
 Claus model 126–7
 colorectal cancer 73
 BRCA1 association 9
 counselling 176
 management of patients with increased risk 177
 risk stratification 176
 see also hereditary non-polyposis colorectal cancer syndrome
 commercial genetic testing 352
 conditionally replicative adenoviruses 375, 378
 confidentiality
 of family medical history 347–8
 of genetic test results 186–7, 348–9
 counselling *see* genetic counselling
 Cowden syndrome (CS) 22–36, 78, 214
 clinical cancer genetic management 32–3
 diagnosis 23–6
 differential diagnosis 30–2
 epidemiology 22–3
 genetics 27–8, 29–30
 cryptic *PTEN* Hamartoma Tumour Syndrome (PHTS) 29–30
 CT scanning, ovarian cancer 277
 cyclin D1 114–15
 cyclin-dependent kinase inhibitors 114
CYP1A1 gene, breast cancer risk and 16
 Cyrillic software program 129–30, 169

 databases 145
 disclosure of genetic test results 186–7, 348–9
 docetaxel 260
 doxorubicin 260, 377
 duty of care 350–1
 dysgerminoma 118

 education 200
 primary care staff 189
 public awareness promotion 201–2, 342–3
 employment issues 188
 endometrial carcinoma
 Cowden syndrome 30, 32, 33, 34, 35
 hereditary non-polyposis colorectal cancer and 74, 178
 tamoxifen and 245
 equity of access 188

396 Index

- ethical issues 187–9
 - commercial genetic testing 352
 - confidentiality of family medical history 347–8
 - disclosure of genetic test results 186–7, 348–9
 - duty of care 350–1
 - employment issues 188
 - equity of access 188
 - gene patenting 351–2
 - insurance issues 188–9, 353–65
 - paternity testing 352–3
 - principle of informed consent 184–6
 - prophylactic mastectomy 342
 - prophylactic oophorectomy 341–2
 - regulation of commercial testing facilities 189
 - stigmatization 189
- etoposide 260, 377
- Fallopian tube cancer 249
- familial adenomatous polyposis (FAP)
 - genetic testing 307
 - registries 197
- Familial Ovarian Cancer Screening Study (FOCSS), UK 225
- family history clinics 286–7
- Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC), France 199
- fibroadenomas, Cowden syndrome 25, 32
- Finnish population 13
- 5-fluorouracil 377
- founder effects 12–13, 49–51
- Gail model 126
- gastric cancer 178
- gene patenting 351–2
- gene therapy 372–81
 - future prospects 380–1
 - principles of 372–4
 - in vitro* delivery 374
 - local delivery 374
 - systemic delivery 374
 - studies of 376–80
 - chemoprotection 380
 - conditionally replicative adenoviruses 378
 - correction of genetic mutation 377–8
 - immunotherapy 379–80
 - molecular chemotherapy 378–9
 - treatment strategies 375–6
- vectors 373
- general practitioners
 - focus groups 148–9
 - referral guidelines 146
 - see also* primary care
- genetic counselling 170, 216
 - breast cancer 172
 - prophylactic mastectomy and 286–7
 - colorectal cancer 176
 - Cowden syndrome 32
 - ovarian cancer 174, 282–3
 - psychological distress and 283, 296–7
- genetic counsellors/nurses 168, 200
- genetic databases 145
- genetic registries 197
- genetics services *see* cancer genetics services
- genetic testing 184–7, 299–302, 306–35
 - attitudes towards 299–300
 - gender differences 300
 - commercial genetic testing 352
 - definition of a genetic test 353–4
 - disclosure of test results 186–7, 348–9
 - effects of results on behaviour 302
 - familial adenomatous polyposis 307
 - hereditary non-polyposis colorectal cancer 307
 - Huntington's disease 307
 - inconclusive results 300–1
 - Li–Fraumeni syndrome 308
 - misinformation about 340–1
 - mutation screening for risk assessment 131–7, 161–2, 299
 - neurofibromatosis type 2 307
 - principle of informed consent 184–6
 - psychological impact of results 301
 - regulation of commercial testing facilities 189
 - von Hippel–Lindau disease 307
 - see also* BRCA1/2 testing
- Genetics and Insurance Advisory Committee (GIAC) 189, 355–7, 358
- glioblastoma multiforme 35
- glutathione S-transferases, breast cancer and 16
- Gorlin (basal cell naevus) syndrome 31, 32
- H-*ras*-1 polymorphism, breast cancer risk and 16–17

397 **Index**

- hChk2 gene mutations 15
- Health Insurance Portability and Accountability Act (1996) 362
- healthcare structure 197–8
- HER2/neu 113, 377–8, 379
- hereditary non-polyposis colorectal cancer syndrome (HNPCC) 73, 74, 82, 178
- breast cancer and 75–6
 - clinical features 74
 - genetic basis 74
 - genetic testing 307
 - insurance issues 364
 - ovarian cancer and 55–6, 75, 76
 - see also* colorectal cancer
- hereditary site-specific ovarian cancer syndrome 53–5
- hormone replacement therapy (HRT)
- breast cancer risk and 240–1
 - combined HRT 240
 - following oophorectomy 212, 249, 280–1
 - with tamoxifen 241, 243
- Human Genetics Advisory Commission (HGAC) 354–5, 363
- Human Genetics Commission (HGC) 357–8
- Huntington's disease (HD) 300, 307, 353
- hysterectomy 252
- Icelandic populations 13, 51, 94
- immunopotiation 376
- immunotherapy 375–6, 379–80
- Imperial Cancer Research Fund (ICRF), UK 199
- informed consent, for disclosure of genetic test results 184–6, 348–9
- Insurance Contracts Act (1984), Australia 362
- insurance issues 188–9, 353–65
- benefits of testing 362–3
 - evidence of discrimination 363–5
 - percentage of policies affected 354
- interleukin 2 (IL-2) 379–80
- International Cowden Consortium 25
- juvenile polyposis syndrome (JPS) 30–1
- Lhermitte–Duclos disease 26
- Li–Fraumeni syndrome 14–15, 214
- genetic testing 308
 - lifestyle modification, breast cancer and 238–41
- LKB1/STK11* mutations 31, 77, 78
- Lynch II syndrome 115
- magnetic resonance imaging (MRI)
- breast cancer screening 257–8
 - ovarian cancer 277
- male breast cancer 131, 213, 238
- malignant melanoma 35
- mammography 157–8, 209, 255–7
- misinformation about 339–40
 - see also* screening
- management of high-risk individuals 173, 178–9, 215–17, 237–61
- early detection 253–9
 - identification of individuals with increased risk 173–7, 178–9, 237–61
 - prevention 238–53
 - treatment 259–61
 - see also* prophylaxis; screening; surveillance
- mastectomy 211, 259
- breast cancer prophylaxis 212, 215, 217, 248–50, 286–92
 - counselling 286–7
 - follow-up 292
 - operative sequence 290–1
 - outcomes 291–2
 - protocol 287–9
 - surgical technique 289–90
 - uptake 292
- ethical issues 342
- psychological impact 249–50
- medullary carcinoma 111
- melphelelan 278
- MENDEL software program 129, 137
- methotrexate 377
- methylation 386
- microsatellite instability (MSI) 74
- misinformation amongst women 339–42
- gene testing 340–1
 - mammography 339–40
 - management options 341–2
 - ovarian screening 340
 - scale of familial cancer risk 341
- mismatch repair (MMR) deficiency 74
- missense mutations 99, 134
- mitoxantrone 260
- MLH1* mutations 74, 75, 76, 82
- MLINK/LINKAGE software package 127

398 Index

- molecular chemotherapy 375, 378–9
MSH2 mutations 74, 75, 76, 82
 multi-drug resistance (MDR) protein 380
 multiple endocrine neoplasia type 2 33
 multiple hamartoma syndrome *see* Cowden syndrome
 Multiple Outcomes Raloxifene Evaluation (MORE) study 246–7
 mutations
 BRCA1 9–10, 49–53, 237–8
 BRCA2 11–12, 49–53, 237–8
 correction of 375, 377–8
 founder effects 12–13, 49–51
 missense mutations 99, 134
 screening for risk assessment 131–7, 161–2, 299
 validity of calculated carrier probability 134–7
 see also specific mutations
 Myhre–Smith syndrome *see* Bannayan–Riley–Ruvalcaba syndrome

N-acetyltransferase (*NAT2*) gene, breast cancer risk and 17
 National Human Genome Research Institute, USA 198
 National Surgical Adjuvant Breast and Bowel Project (NSABP) trials 91, 242, 245, 247
 neurofibromatosis type 1 (NF-1) 31–2
 neurofibromatosis type 2 (NF-2) 307
 Nuffield report 185, 186, 188

 oestrogen receptor (ER), in breast cancer 112–13, 241–2, 247
 oophorectomy
 breast cancer prevention 91, 212, 214–15, 216–17, 249–50
 ethical issues 341–2
 HRT and 212, 249, 280–1
 ovarian cancer prevention 251–2, 280–2
 psychological impact 249–50
 oral contraceptive pill
 breast cancer risk and 251, 280
 ovarian cancer protection 115, 213–14, 250–1, 279–80
 ovarian cancer 43, 115, 275–83
 associated genetic syndromes
 hereditary non-polyposis colorectal cancer syndrome (HNPCC) 55–6, 75, 76, 178
 Peutz–Jeghers syndrome 77–8
 surveillance recommendations 78–9
 borderline ovarian neoplasms 119
BRCA1-associated ovarian cancer 9, 49–53, 55, 213–14
 age of onset 57
 genotype–phenotype associations 58
 grade and stage 58, 118
 lifetime risk 238
 malignant germ-cell and stromal-cell neoplasms 118–19
 natural history 60–1
 peritoneal cancer and 59–60
 pre-malignant and early invasive lesions 59
 tumour pathology 57–8, 116–17
 see also BRCA1
BRCA2-associated ovarian cancer 12, 49–53, 55, 213–14
 age of onset 57
 genotype–phenotype associations 58–9
 grade and stage 58, 118
 malignant germ-cell and stromal-cell neoplasms 118–19
 natural history 60–1
 peritoneal cancer and 59–60
 pre-malignant and early invasive lesions 59
 tumour pathology 57–8, 117–18
 see also BRCA2
 breast cancer relationships 7, 48, 49–53
 classification 116
 counselling 174, 282–3
 epidemiology 43–5
 familial aggregation 45–9
 hereditary site-specific ovarian cancer syndrome 53–5
in situ neoplastic change 119
 management 261, 277–9
 chemotherapy 261, 278–9
 neoadjuvant chemotherapy with interval debulking 279
 palliative care 279
 surgery 277–8
 see also gene therapy
 presentation 276
 prevention 250–3, 279–82
 oophorectomy 251–2, 280–2

399 **Index**

- oral contraceptive pill 115, 213–14, 250–1, 279–80
- tubal ligation 252–3
- prognosis 220
- referrals 159–60
- risk factors 43–4
- risk prediction models 56–7
- risk stratification 174
- screening 178–9, 220–31, 253–4, 258
 - available data 224–5
 - CA125 levels 222–3, 224, 225, 277
 - current practice 225
 - current screening strategies 224
 - current trials 225–6
 - misinformation about 339–40
 - reasons for screening 220–1
 - reasons not to screen 221
 - requirements of screening test 222
 - screening tests in use 222–4
 - ultrasound 223–4, 258, 277
- survival 60–1, 220
- see also* management of high-risk individuals
- ovarian cancer cluster region (OCCR) 58–9
- p53 protein 377
 - breast cancer 113–14
 - mutation correction 377
- paclitaxel 260, 278–9, 377
- palliative care, ovarian cancer 279
- paternity testing 352–3
- pedigree analysis 126–31, 169, 315
- penetrance
 - BRCA1* 9–10
 - BRCA2* 12
 - Li–Fraumeni syndrome 14
 - low penetrance genes 15–17
- peritoneal cancer 59–60, 281–2
- Peutz–Jeghers polyp 31
- Peutz–Jeghers syndrome (PJS)
 - breast cancer in 77–8
 - differential diagnosis 30, 31
 - ovarian cancer in 77–8
- prevention *see* prophylaxis
- primary care 144
 - education and training 189
 - identification of individuals with increased risk 167–8
 - see also* general practitioners; referrals
- progesterone receptor (PgR), breast cancer 113
- prognosis
 - breast cancer 95–8
 - ovarian cancer 220
 - see also* survival
- prohibitin 385
- prophylaxis
 - breast cancer 212, 214–15, 238–50
 - chemoprevention 91–2, 212, 215, 241–8
 - first primary breast cancer 238–50
 - lifestyle modification 238–41
 - mastectomy 212, 215, 217, 248–50, 286–92
 - oophorectomy 91, 212, 214–15, 216–17
 - second primary breast cancer 250
 - ethical issues regarding prophylactic surgery 341–2
 - ovarian cancer 250–3
 - oophorectomy 251–2
 - oral contraceptive pill 213–14, 250–1
 - tubal ligation 252–3
 - psychological impact of surgical prophylaxis 249–50
- prostate cancer
 - BRCA1* association 9, 238
 - chemoprevention 253
 - screening 258–9
- prostate specific antigen (PSA) 258
- Proteus syndrome 31
- Proteus-like syndrome 22, 28, 31
- PS2 protein 113
- psychological distress
 - amongst previously affected women 297–8
 - anxiety exacerbation and alleviation 343–4
 - counselling and 283, 296–7
 - genetic test results and 301
 - effects on behaviour 302
 - perception of risk 298–9
 - prophylactic surgery and 249–50
 - referral eligibility and 344
 - screening and 254
- PTEN* function 36
- PTEN* Hamartoma Tumour Syndrome (PHTS) 29, 30
- cryptic PHTS 29–30

400 Index

- PTEN* mutations
 Bannayan–Riley–Ruvalcaba syndrome (BRR) 22, 28–9, 33
 Cowden syndrome (CS) 22, 28, 29–30
 Proteus-like syndrome 22, 28
 sporadic tumours 33–6
 public awareness and education 201–2, 342–3
- radiotherapy, breast cancer 90–1, 211, 259–60
- raloxifene 241, 246
 breast cancer prevention 246–8
- referrals 157–63
 breast cancer 159
 eligibility 344–5
 guidelines 146–7, 158–9
 ovarian cancer 159–60
 risk assessment 160–2
 methods 160–1
 molecular genetic testing 161–2
- registries 197
- RET* proto-oncogene mutations 33
- retrotransposons 387
- risk assessment 126, 160–2, 168–70
 guideline-based approach 170
 mutation screening 131–7, 161–2, 299
 validity of calculated carrier probability 134–7
 pedigree analysis 126–31, 169
 prediction models 56–7, 126–7, 169–70
- risk factors
 breast cancer 160
 family history 6–7
 HRT 240–1
 oral contraceptive pill 251, 280
 ovarian cancer 43–4
- risk perception 298–9
 misinformation 341
- Ruvalcaba–Riley–Smith syndrome *see*
 Bannayan–Riley–Ruvalcaba syndrome
- salpingectomy 249
- screening
 breast cancer 91, 157–8, 178–9, 253–8
 clinical examination 255
 examination methods 210
 interval between examinations 210
 magnetic resonance imaging 257–8
 mammography 157–8, 209, 255–7
 misinformation about 339–40
 population vs high-risk group screening 208–10
 self-examination 255
 ultrasonography 257
 costs and benefits 158, 179–84
 implementation 190
 mutation screening for risk assessment 131–7, 161–2, 299
 validity of calculated carrier probability 134–7
 ovarian cancer 178–9, 220–31, 253–4, 258
 available data 224–5
 CA125 levels 222–3, 224, 225, 277
 current practice 225
 current screening strategies 224
 current trials 225–6
 misinformation about 339–40
 reasons for screening 220–1
 reasons not to screen 221
 requirements of screening test 222
 screening tests in use 222–4
 ultrasound 223–4, 258, 277
 prostate cancer 258–9
- Select Committee on Science and Technology 185, 188–9
- selective oestrogen receptor modulators (SERMs) 246–8
see also raloxifene; tamoxifen
- self-examination of breasts 255
- service provision *see* cancer genetics services
- SMAD4* mutations 31
- smoking, breast cancer risk and 17, 239–40
- standards 195
- steroid hormone receptors, breast cancer 112–14
c-erb-b2 113
TP53 113–14
- stigmatization 189
- STK11/LKB1* mutations 31, 77, 78
- Study of Tamoxifen and Raloxifene (STAR) 247
- surveillance 73, 178, 387–8
 breast cancer 91, 216, 217
 Cowden syndrome 32–3, 79
 discontinuation of 344–5
 eligibility criteria 344–5
 hereditary non-polyposis colorectal cancer 78–9

Cambridge University Press

052180373X - Familial Breast and Ovarian Cancer: Genetics, Screening and Management

Edited by Patrick J. Morrison, Shirley V. Hodgson and Neva E. Haites

Index

[More information](#)**401** **Index**

- Peutz–Jeghers syndrome 78–9
 - see also* screening
- survival
 - breast cancer 82–3, 207–8
 - linkage-based studies 92–4
 - mutation-based studies 94–100
 - prospective studies 207–8
 - retrospective studies 208
 - ovarian cancer 60–1, 220
 - screening benefits 158
- T-cell-receptor signalling chain 380
- tamoxifen 241
 - breast cancer prevention 91–2, 242–6, 247–8
 - breast cancer treatment 241
 - breast density and 245
 - endometrial cancer and 245
 - with HRT 241, 243
- thymidine kinase (TK) 378–9
- thyroid cancer 33
 - Cowden syndrome 25, 32, 33, 34–5
- tobacco smoking, breast cancer risk and 17, 239–40
- TP53* mutations
 - breast cancer 113–14
 - Li–Fraumeni syndrome 15
- training 200
 - primary care staff 189
- transforming growth factor β 1 gene 385
- transposons 387
- tubal ligation, ovarian cancer risk and 252–3
- tumour suppressor gene silencing 386–7
- ultrasound screening
 - breast cancer 257
 - ovarian cancer 223–4, 258, 277
- von Hippel–Lindau disease 307
- Welsh Cancer Genetics Service 146–56
 - aims 149
 - benchmark development 150–2
 - evaluation 147–9, 150
 - future prospects 153–6
 - primary care 146
 - referral guidelines 146–7
 - service delivery and information technology 152–3
 - steering group 149